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OBJECTIVES AND STUDY: Proton pump inhibitors (PPI) are one of the most
widely prescribed classes of medications for pediatric and adult patients. In
the last decade there are increasing reports of safety concerns regarding PPI
use including the risk of fractures. Among the pediatric population, fractures
represent a commonly encountered pathology and are associated with
significant morbidity and economic burden. Few studies have evaluated PPI
use and fracture risk among pediatric patients. We performed a retrospective
propensity-matched analysis to compare the rate of fracture among pediatric
patients prescribed PPI with those patients who did not receive PPI.
METHODS: Initial encounters for patients 6 months to 15.5 years were
identified between 06/01/2011 to 12/31/2015 in the Pediatric Hospital
Information System (PHIS) database, a database with encounters from 49
children’s hospitals in the United States. Encounters for patients outside the
stated age range, encounters related to chronic illnesses, and encounters for
patients with conditions or medications predisposing to fracture were
excluded. Encounters were classified as PPI encounters if a charge for PPI was
documented in the billing record. PPI encounters were propensity matched to
non-PPI encounters on the basis of hospital, age, race, sex, payer, encounter
type, median household income quartile, intensity of resource utilization and
3M’s All Patient Refined Diagnostic Related Group. Following initial
encounter, patients were evaluated over a 2-year period for hospitalizations
resulting from fracture. Categorical variables for PPI encounters and non-PPI
encounters were compared using a Chi-square test. Continuous variables
were compared using Wilcoxon rank-sum test.
RESULTS: Data from 32,001 healthcare encounters with documentation of PPI
use were propensity matched to the same number of encounters with no
documentation of PPI use. PPI encounters had median age of 4 years with a
distribution of 0 to 3 years (48.8%), 4 to 8 years (15.2%), 9 to 13 years
(23.9%), and greater than 14 years of age (12.1%). 48.5 % of the PPI cohort
was female. We found a statistically significant higher rate of fractures among
the PPI exposed group (1.4% vs 1.2%, p = 0.019). Adjusting for remaining
differences in sex, race, encounter type, payer, and resource intensity after
matching, the difference remained statistically significant (p = 0.017) with an
adjusted odds ratio (95% confidence interval) of 1.2 (1.0,1.4). Among all
patients with fractures, upper extremity was the most common location,
however the PPI cohort was more likely to suffer from lower extremity, rib,
and spinal fracture compared to the control group (p = 0.01). We found no

relationship between fracture risk and individual proton pump inhibitors (p =
0.205).
CONCLUSIONS: This study suggests an increased risk of fracture among
otherwise healthy pediatric patients taking PPI. Among patients hospitalized
with a fracture, those documented as being prescribed PPI had a higher rate of
lower extremity, rib, and spine fractures compared to controls and appeared
to be a class effect not related to individual PPI agent. Future studies
capturing data on duration of use, dosage, and mechanism are needed to
further evaluate this relationship.

